Renovaro Management
Management criteria checks 1/4
Renovaro's CEO is David Weinstein, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.16% of the company’s shares, worth $198.10K. The average tenure of the management team and the board of directors is 0.2 years and 3.4 years respectively.
Key information
David Weinstein
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | 0.2% |
Management average tenure | less than a year |
Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14CEO
David Weinstein (63 yo)
less than a year
Tenure
Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. He was Managing Director of Investment Banking of Dawson James Securities, Inc. Prior to joining Dawso...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive VP for Research & Development | less than a year | US$430.29k | 0% $ 0 | |
CEO & Director | less than a year | no data | 0.16% $ 198.1k | |
Co-Founder & Inventor | no data | no data | 11.12% $ 14.0m | |
Chief Financial Officer | no data | no data | no data | |
Senior Vice President for Clinical Operations | 2.8yrs | no data | no data |
0.2yrs
Average Tenure
60yo
Average Age
Experienced Management: RENB's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | less than a year | no data | 0.16% $ 198.1k | |
Independent Director | less than a year | no data | no data | |
Member of Respiratory Diseases Scientific Advisory Board | 3.4yrs | no data | no data | |
Member of HBV Scientific Advisory Board | 3.4yrs | no data | no data | |
Chairperson of HBV Cure Scientific Advisory Board | 4.5yrs | US$129.74k | 0% $ 0 | |
Member of HBV Scientific Advisory Board | 4.5yrs | no data | no data | |
Independent Director | less than a year | no data | no data | |
Independent Director | less than a year | no data | no data | |
Chairman of HIV Scientific Advisory Board | 6.5yrs | no data | no data | |
Member of HIV Scientific Advisory Board | 7yrs | no data | no data | |
Member of HBV Scientific Advisory Board | 4.5yrs | no data | no data | |
Chairman of Scientific Advisory Board | less than a year | no data | no data |
3.4yrs
Average Tenure
72yo
Average Age
Experienced Board: RENB's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/12 11:23 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Renovaro Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|